A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Study Number

3718023

Phase

Age Group

Adult

Principal Investigator

Purpose

An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer

Check your eligibility for this trial

Check now

Full Title

An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer

ClinicalTrials.Gov ID

NCT06179069

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.